Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

GRIPonMASH GRIP on MASH: Global Research Initiative for Patient Screening on MASH

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€14.0m
Total cost
€26.2m
Partners
40 organisations in 14 countries
Type
Research and Innovation Action
Grant agreement
101132946

What the project is doing

In the project's own words, from its summary on CORDIS.

GRIP on MASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Together with seven medical technology, pharmaceutical and biotechnology companies, we will devise a sustainable and scalable GRIP on MASH Platform that will enable access to at-risk patients developing or having MASLD through the early detection of this condition at the primary care level.

This Platform will allow A) the early detection of patients with MASLD: distributed in 12 European Centers of Excellence (CoEs), 10,000 patients at high risk of MASLD - defined as patients with type-2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension - will be screened and characterized; B) better patients’ stratification: the Platform will comprise artificial intelligence-based decision support tools that will make use of existing and novel biomarkers/biomarker combinations.

Their predictive accuracy will be tested at the primary care level; there we will perform multi-OMICs analysis (proteomics, lipidomics, metabolomics, genomics, metagenomics and fluxomics) in fasted blood samples and we will explore imaging biomarkers/organ-on-a-chip to find future non-invasive diagnostic alternatives for the current standard (liver biopsies); and C) personalized lifestyle advice, by exploring evidence-based lifestyle features and the effect of nutritional recommendations: among the cohorts at the CoEs, we will use validated questionnaires to assess physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress.

Integrating patients’ perspectives with the participation of two patient organizations, the trustworthiness and sustainability of our GRIP on MASH Platform will be assessed by investigating potential economic, ethical and regulatory barriers to its future adoption. GRIP on MASH will change healthcare practice in MASLD and reduce the disease burden for patients.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
European Liver Patients AssociationBruxelles / BrusselBelgiumParticipant
Liver Patients InternationalBruxelles / BrusselBelgiumParticipant
Universitair Ziekenhuis AntwerpenEdegemBelgiumParticipant
Universite Libre De BruxellesBruxellesBelgiumParticipant
Roche Diagnostics International AGRotkreuzSwitzerlandParticipant
Vseobecna Fakultni Nemocnice V PrazePraha 2CzechiaParticipant
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyParticipant
Universitat Des SaarlandesSaarbruckenGermanyParticipant
Evido ApsCopenhagenDenmarkParticipant
Nordic Bioscience A/sHerlevDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Charokopeio PanepistimioAthinaGreeceParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Servicio Andaluz De SaludSevillaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceThird party
Biocellvia SASMarseilleFranceParticipant
EchosensParisFranceParticipant
Fondation Cardiometabolisme NutritionParisFranceParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyThird party
Universita Cattolica Del Sacro CuoreMilanoItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Boehringer Ingelheim B.V.amsterdamNetherlandsAssociatedpartner
Elevate BVUtrechtNetherlandsParticipant
Exit071 BVLeidenNetherlandsParticipant
Julius Clinical Research BVZeistNetherlandsParticipant
Mimetas BVLeidenNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Sint Franciscus VlietlandgroepRotterdamNetherlandsParticipant
Stichting Wetenschappelijk Onderzoek Stichting Wetenschappelijk Onderzoek FranciscusRotterdamNetherlandsThird party
Universiteit LeidenLeidenNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Associação para Investigação e Desenvolvimento da Faculdade de MedicinaLisbonPortugalParticipant
Medical Education Research and Innovation Center S.r.l.BucurestiRomaniaParticipant
European Atherosclerosis SocietyGoteborgSwedenParticipant
Mercodia AktiebolagUppsalaSwedenParticipant
VLVbio ABStockholmSwedenParticipant
Metadeq LimitedLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI